Compare iShares MSCI Hong Kong ETF (EWH) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Incyte Corporation — how do they compare? iShares MSCI Hong Kong ETF trades at $22.46, while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals.
| EWH | INCY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $129.93 |
52-Week Low | $20.66 | $81.61 |
Market Cap | — | $24.54B |
Enterprise Value | — | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH trades at $22.45, down 1.54% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent news highlights the Hang Seng Index's rebound and potential golden cross formation, driven by technology stock recoveries. The ETF shows no available fundamental ratios in the provided data, but tracks Hong Kong equities, with a dividend scheduled for June 2026.
Outlook hinges on Hong Kong market performance and tech sector momentum. Risks include Asian market volatility and geopolitical factors. Analyst sentiment is mixed, with some bullish on Hong Kong over Korea, while technicals suggest caution near support at $22.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
